Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A clear, practice-focused summary of the 2026 ASCO living guideline on systemic treatment of metastatic castration‑resistant prostate cancer, emphasizing biomarker-driven choices, sequencing, and new options such as 177Lu‑PSMA and PARP inhi
A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to d
This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary tre
A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS
A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p
CheckMate 7DX demonstrates that adding nivolumab to docetaxel fails to improve survival outcomes in ARPI-pretreated, chemotherapy-naive mCRPC, while significantly increasing toxicity and treatment-related mortality.
Final MAGNITUDE results show niraparib combined with abiraterone–prednisone improves radiographic PFS, time to symptomatic progression and delays cytotoxic chemotherapy in HRR‑altered mCRPC (notably BRCA1/2), preserves patient‑reported qual
A meta-analysis of six randomized trials shows [177Lu]Lu‑PSMA significantly increases PSA and objective responses and reduces risk of radiographic progression, with no significant increase in high‑grade toxicity and no clear overall surviva
![[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis](https://news.medxy.ai/wp-content/uploads/2025/11/9d3c0201-d1b3-49f2-a408-3ea3d0347451-600x600.jpg)
PSMAfore shows that [177Lu]Lu-PSMA-617 given to taxane‑naive, PSMA-positive mCRPC patients delays worsening of health-related quality of life, pain, and first symptomatic skeletal events versus switching AR pathway inhibitors.
In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.
Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematol
Final TALAPRO-2 data show that adding talazoparib to enzalutamide improves overall survival and rPFS in metastatic castration‑resistant prostate cancer, with the largest benefit in BRCA1/2‑altered tumors; hematologic toxicity is common but
The phase 3 CYCLONE 2 trial found that adding the CDK4/6 inhibitor abemaciclib to abiraterone did not significantly prolong radiographic progression‑free survival in men with metastatic castration‑resistant prostate cancer and increased tox
Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…
The CONTACT-02 phase 3 trial shows cabozantinib plus atezolizumab improves progression-free survival but not overall survival in advanced mCRPC post-ARPI, offering a novel non-androgen receptor-based option.